BLFS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
BioLife Solutions Inc (BLFS) is not a strong buy for a beginner, long-term investor at this moment. While the company's fundamentals show potential for growth, the lack of recent positive trading signals, insider selling, and declining financial metrics suggest waiting for a better entry point.
The stock's MACD is positive but contracting, RSI is neutral at 65.163, and moving averages are converging, indicating no clear trend. The stock is trading near resistance levels (R1: 21.1), with a pivot at 20.017.
Analyst Carl Byrnes views the stock as a 'Top Pick 2026' and highlights improving fundamentals and durable growth potential. The biopreservation media platform is becoming a standard in cell and gene therapy.
Insiders are selling heavily, with a 3374.62% increase in selling activity over the last month. Financial performance in Q4 2025 showed declining net income (-11.15% YoY), EPS (-14.81% YoY), and gross margin (-9.61% YoY).
In Q4 2025, revenue increased by 24.34% YoY to $18.785M, but net income dropped by 11.15%, EPS decreased by 14.81%, and gross margin fell by 9.61%.
Analyst Carl Byrnes reiterates BLFS as a 'Top Pick 2026' and sees the recent pullback as a compelling buying opportunity, citing improving fundamentals and durable growth with FY26 revenue guidance projecting 17%-20% YoY growth.
